Hyponatremia – predictor of adverse prognosis in cirrhosis

Bengus A, Babiuc RD
Gastroenterology Department, University Emergency Hospital, Bucharest

Correspondence to: Andreea Bengus, MD
University Emergency Hospital Bucharest, 169 Splaiul Independentei, Bucharest
Phone: +40 744 497 626; E-mail: andreeabengus@yahoo.com

Received: February 8th, 2012 – Accepted: May 25th, 2012

Abstract
Hyponatremia is a frequent complication of the advanced liver disease, being, as the hepatorenal syndrome, a consequence of the important circulatory dysfunction of cirrhosis. Hyponatremia is determined by the impaired capacity of the kidney to excrete free water, which leads to water retention disproportionate to sodium retention, thus causing low plasma osmolarity. Hyponatremia in cirrhosis is associated with a high morbidity and mortality, its presence suggesting a very advanced liver disease. Current evidence suggests that hyponatremia affects the brain function and predisposes to hepatic encephalopathy. In addition, hyponatremia is a risk factor for liver transplantation, being associated with a high frequency of complication and affecting short and long-term post-transplant survival.

Keywords: hyponatremia, hypo-osmolarity, circulatory dysfunction, hepatorenal syndrome

Cirrhosis is characterized by a progressive circulatory dysfunction, including systemic arterial vasodilatation and reduced peripheral resistance, which induces renal hypoperfusion. Renal hypoperfusion represents the stimulus that activates the renin-angiotensin aldosteron system having as consequence sodium and water retention [1].

Hyponatremia in cirrhosis was first described in the 1950’s, but its importance was overlooked for many years. 30 years later its importance as a predictor for the survival in cirrhosis was investigated [2,3].

Definitions
Currently, hyponatremia in cirrhosis is defined as having a serum sodium level below 130 mmol/l [4]. According to this definition, the prevalence of hyponatremia in cirrhotic patients is of about 21.6%. If the cut-off limit for serum sodium is considered to be of 135 mmol/l (that represents the lower limit of serum sodium in healthy subjects), then the prevalence is of about 49.4% [5].

Cirrhotic hyponatremia is associated with jaundice, hepatic encephalopathy, refractory ascites and hepatorenal syndrome [5]. Serum sodium in cirrhosis that is below 130 mmol/l is associated with a median transplant-free survival of less than 6 months [6].

2 types of hyponatremia have been described in cirrhotic patients:
- Hyponatremia – this condition is due to important losses of extracellular fluids (excess of diuretics or losses in the gastrointestinal tract); it is characterized by low serum sodium and low plasma volume. The patients do not have ascites or edema; they have signs of dehydration and prerenal azotemia.
- Hypovolemic hyponatremia – also named dilutional hyponatremia. This condition is associated with large ascites (frequently refractory ascites) and edema. It is caused by the renal impairment in excretion of solute-free water, causing disproportionate water retention compared to sodium. Therefore, in this case, the plasma volume is expanded in absolute value, but it is low compared to the marked arterial dilatation characteristic to advanced cirrhosis.

Because most of the time hyponatremia characterizes advanced cirrhosis (when the patients also have many other derangements), it is difficult to identify the clinical manifestations induced by hyponatremia per se.

Hepatic encephalopathy is the most important clinical complication of hyponatremia. Besides this, hyponatremia is associated with other complications of cirrhosis. In the majority of patients, it occurs together with acute kidney injury or even HRS, and thus, correlates with a poor prognosis. It is important to know that cirrhotic patients with hyponatremia are at very high risk of developing the hepatorenal syndrome [7]. In this situation, probably, hyponatremia is due to increased levels of arginine vasopressine (HRS is characterized by intense stimulation of the renin angiotensin aldosterone system due to an extreme systemic vasodilatation) and to
reduced glomerular filtration rate and increased proximal tubular sodium reabsorption [8].

Cirrhotic patients with hyponatremia are found more frequently in cases of bacterial infections [9].

Several lines of evidence support the existence of a correlation between hyponatremia and hepatic encephalopathy. Levels of serum sodium and ammonia determine the major electroencephalographic changes in cirrhosis [10]. The novel theories suggest that low-grade cerebral edema (which can be induced by hyponatremia) may play a part in the pathogenesis of hepatic encephalopathy [11]. This low-grade cerebral edema, resulting from the swelling of the astrocytes (maybe by increased intracellular content of glutamine, resulted from ammonia metabolism) is responsible for a number of alterations of the neurological functions, which can lead to hepatic encephalopathy. In this context of the existence of low-grade cerebral edema, hyponatremia plays an important role in increasing the osmotic pressure on the astrocytes. In this situation, only small increases in ammonia levels can induce clinically manifested hepatic encephalopathy.

After liver transplantation, once the important circulatory dysfunction induced by hepatic failure is removed, serum sodium levels improves rapidly, however, the risk of central pontine myelinolysis in the early postoperative period still exists [12,13].

The impact of serum sodium on the prognosis in patients with advanced liver disease was evaluated in a study that included over 6000 patients, candidates for liver transplantation in the United States [14]. The hazard rate for death was of 1.05 per 1 mmol/l decrease in serum sodium at values between 140 and 125 mmol/l.

2 studies [15,16] suggested that pretransplant hyponatremia is associated with a high risk of neurological complications, of renal failure and infectious complications, longer hospitalization and with an increased short-term mortality rate after transplantation. Another study [17] showed that among cirrhotic patients with normal serum sodium that underwent liver transplantation, those with a history of hyponatremia in the preceding 6 months had poorer outcomes. Thus, the correction of serum sodium seems not to eliminate the associated mortality risk.

In addition, cirrhosis hyponatremia affects the quality of life of the patients because they require a fluid intake restriction in order to prevent further dilution, and is usually not very well tolerated. In a recent study [18], hyponatremia was an independent predictive factor of the altered quality of life in a patient with cirrhosis.

However, data available until now suggest that hyponatremia in cirrhosis is only a manifestation of the profound circulatory dysfunction, and that correction of hyponatremia per se has only limited benefits if the underlying circulatory condition is not improved.

References

1. Gines P, Guevara M. Hyponatremia in cirrhosis: pathogenesis, clinical significance and management. Hepatology. 2008; 48:1002–1010.

2. Arroyo V, Rodes J, Gutierrez-Lizarraga MA, Revert L. Prognostic value of spontaneous hyponatremia in cirrhosis with ascites. Am J Dig Dis. 1976; 21: 249–256.

3. Llach J, Gines P, Arroyo V, Rimola A, Tito L, Badalamenti S. Prognostic value of arterial pressure, endogenous vasoactive systems and renal function in cirrhotic patients admitted to the hospital for the treatment of ascites. Gastroenterology. 1998; 94: 482–487.

4. Gines P, Berl T, Bernardi M, Bichet DG, Hamon G, Jimenez W. Hyponatremia in cirrhosis: from pathogenesis to treatment. Hepatology. 1998; 28: 851–864.

5. Angeli P, Wong F, Watson H, Gines P. Hyponatremia in cirrhosis: results of a patient population survey. Hepatology. 2006; 44: 1535–1542.

6. Heuman DM, Abou-Assi SG, Habib A. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology. 2004; 40: 602–610.

7. Gines A, Escorsell A, Gines P, Sala J, Jimenez W, Ingla da L. Incidence, predictive factors and prognosis of hepatorenal syndrome in cirrhosis. Gastroenterology. 1993; 105: 229–236.

8. Gines P, Cardenas A, Schrier RW. Liver disease and the kidney. In: Liver disease and the kidney. Philadelphia, PA: Lippincott Williams & Wilkins, 2000.

9. Follo A, Llovet JM, Navasa M, Planas R, Forns X, Franci torra A. Renal impairment after spontaneous bacterial peritonitis in cirrhosis: course, predictive factors and prognosis. Hepatology. 1994; 20: 1495–1501.

10. Amadio P, Del Piccolo F, Petteno E, Mapelli D, Angelli P, Iemmolo R. Prevalence and prognostic value of quantified electroencephalogram alterations in cirrhotic patients. J Hepatol. 2001; 35: 37–45.

11. Haussinger D. Low grade cerebral edema and the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology. 2006; 43: 1187–1190.

12. Abbasoglu O, Goldstein RM, Vodpally MS, Jennings LW, Levy MF, Husberg BS. Liver transplantation in hyponatremia patients with emphasis on central pontine myelinolysis. Clin Transplant. 1998; 12: 263–269.

13. Wszolek ZK, McComb RD, Pfeiffer RF, Steg RE, Word RP, Shaw BW Jr. Pontine and extrapontine myelinolysis following liver transplantation. Relationship to serum sodium. Transplantation. 1989; 48: 1006-1012.

14. Kim WR, Biggins SW, Kremers WK. Hyponatremia and mortality among patients on the liver–
transplant waiting list. N Engl J Med. 2008; 359: 1018.

15. Londono MC, Guevara M, Rimola A, Navasa M, Taura P, Mas A. Hyponatremia impairs early post transplantation outcome in patients with cirrhosis undergoing liver transplantation. Gastroenterology. 2006; 130: 1135-1143.

16. Dawwas MF, Lewsey JD, Neuberger JM, Gimson AE. The impact of serum sodium concentration on mortality after liver transplantation: a cohort multicenter study. Liver Transpl. 2007; 13: 1115-1124.

17. Hackworth WA, Heuman DM, Sanyal AJ. Effect of hyponatremia on outcomes following orthotopic liver transplantation. Liver Int. 2009; 29: 1071–1077.

18. Konstam MA, Ghiorghiade M, Burnett JC Jr. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. LAMA 2007; 297: 1319–1331.